Abramson Cancer Center at Penn Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).

402 total trials 74 currently recruiting 235 completed early-phase tilt top decile by trial count

Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.

Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.

Top-decile sponsor footprint

Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 49/100

235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

402 total, page 8 of 9

COMPLETED Phase 1

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

NCT01028885
COMPLETED NA

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

NCT01004718
COMPLETED Phase 1

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT01017133
COMPLETED NA

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

NCT01013337
COMPLETED Phase 1

A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma

NCT01020292
COMPLETED Phase 2

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

NCT00948935
COMPLETED

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

NCT01026337
TERMINATED Phase 1

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

NCT00915694
COMPLETED NA

Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx

NCT01020097
COMPLETED Phase 1

Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors

NCT01018108
COMPLETED Phase 1

Intrapleural Gene Transfer for Pleural Mesothelioma

NCT01212367
COMPLETED Phase 1

Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors

NCT00978081
COMPLETED Phase 2

Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors

NCT01005108
COMPLETED NA

Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment

NCT01018901
COMPLETED

MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer

NCT00984074
COMPLETED NA

Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer

NCT00892515
COMPLETED Phase 1

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

NCT00909831
COMPLETED Phase 2

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

NCT00783367
COMPLETED Phase 1

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00714181
TERMINATED NA

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

NCT00978874
TERMINATED Phase 1

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00955942
COMPLETED Phase 1

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00683241
COMPLETED Phase 2

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

NCT00647426
COMPLETED Phase 1

HPPH and PDT for Pleural Malignancy

NCT01673074
COMPLETED Phase 2

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00589420
COMPLETED Phase 1

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

NCT00780104
COMPLETED Phase 1

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00589056
COMPLETED Phase 2

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

NCT00472693
COMPLETED Phase 1

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

NCT00374933
COMPLETED Phase 2

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

NCT00602602
TERMINATED Phase 1

Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

NCT00776373
TERMINATED Phase 2

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

NCT00602329
COMPLETED Phase 1

Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00128635
COMPLETED Early Phase 1

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

NCT02157831
COMPLETED Phase 2

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

NCT00602576
COMPLETED Phase 1

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

NCT00107211
COMPLETED NA

Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer

NCT00599989
TERMINATED Phase 2

Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

NCT00601848
COMPLETED Phase 1

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

NCT00079157
COMPLETED Phase 1

Study of Bexarotene in Patients With Acute Myeloid Leukemia

NCT00316030
COMPLETED Phase 1

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

NCT02225002
COMPLETED Phase 1

Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer

NCT00077519
COMPLETED Phase 1

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

NCT00066404
TERMINATED Phase 1

Study of Temzolomide and Gleevec in Advanced Melanoma

NCT00667953
COMPLETED Phase 1

Infusional C-myb ASODN in Advanced Hematologic Malignancies

NCT00780052
COMPLETED Phase 1

Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00025480
COMPLETED NA

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

NCT00003736
TERMINATED Phase 2

Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer

NCT00003777
COMPLETED NA

MRI to Detect Breast Tumors in Women

NCT00003302
COMPLETED Phase 1

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

NCT00002902
← Previous Page 8 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 113
Phase 2 62
Phase 3 1
Phase 4 2

Therapeutic Areas

Breast Cancer 20
Cancer 9
Lung Cancer 6
Prostate Cancer 6
Ovarian Cancer 5
Cardiotoxicity 4
Tobacco Use 4
Colorectal Cancer 4
Head and Neck Cancer 4
Cigarette Smoking 3

What is open in the Abramson Cancer Center at Penn Medicine pipeline

74 recruiting of 402 indexed (18% open); 235 completed (58%).

Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide

Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 10%15%20%25% Total trials Recruiting share Abramson Cancer Center at Penn MedicineCase Comprehensive Cancer CenterUniversity of NebraskaTakedaUniversity of Kansas Medical CenterUniversity of Maryland, BaltimoreHenry Ford Health SystemNew York Institute of TechnologyUniversity of California, San Diego
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 402 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Abramson Cancer Center at Penn Medicine page

402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.

  • 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.